Federal Register of Legislation - Australian Government

Primary content

PB 64 of 2019 Determinations/Health as made
This determination amends the National Health (Originator Brand) Determination 2015 (PB 100 of 2015) to determine originator brands of pharmaceutical items for three drugs moving to the F2 formulary.
Administered by: Health
Registered 30 Jul 2019
Tabling HistoryDate
Tabled HR31-Jul-2019
Tabled Senate01-Aug-2019
To be repealed 14 Nov 2019
Repealed by Division 1 of Part 3 of Chapter 3 of the Legislation Act 2003

PB 64 of 2019

National Health (Originator Brand) Amendment Determination 2019 (No. 5)

National Health Act 1953

I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Determination under subsection 99ADB (6B) of the National Health Act 1953.

Dated        26  July 2019

 

 

 

 

 

 

THEA DANIEL

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health



1              Name of Determination

                 (1)     This Determination is the National Health (Originator Brand) Amendment Determination 2019 (No. 5).

(2)     This Determination may also be cited as PB 64 of 2019.

2              Commencement

                This Determination commences on 1 August 2019.

3              Amendments to PB 100 of 2015

                Schedule 1 amends the National Health (Originator Brand) Determination 2015 (PB 100 of 2015).


Schedule 1     Amendments

(section 3)

[1]                   Schedule 1 (after table item 106)

insert:

106A

Hydromorphone

Dilaudid

Dilaudid-HP

Injection

 

Dilaudid

Jurnista

Oral

 

[2]                   Schedule 1 (after table item 224B)

insert:

224C

Tenofovir with emtricitabine and efavirenz

Atripla

 

 

[3]                   Schedule 1 (after table item 233A)

insert:

233B

Trastuzumab

Herceptin

Herceptin SC